



Viscoelastic System
DuoVisc

GENUINE
Chondroitin Sulfate
PROTECTION

Only One System Delivers the Shield of **PROTECTION.**

DuoVisc® Viscoelastic System offers both the endothelial protection of chondroitin sulfate in VISCOAT® OVD with the proven mechanical protection and space maintenance found in PROVISCOAT® OVD.¹

Alcon

GENUINE
Chondroitin Sulfate
PROTECTION

Viscoelastic System
DuoVisc

One System. No Compromises.

ONLY ONE SYSTEM DELIVERS ...

The Proven Protection of Chondroitin Sulfate Found in VISCOAT® OVD


- Only dispersive OVD offering the protection of 4% Chondroitin Sulfate.
- Optimized concentration of Chondroitin Sulfate gives VISCOAT® OVD three negative charges for protection versus one for Sodium Hyaluronic acid containing products, for greater binding to the corneal endothelium.²



— PLUS —

The Mechanical Protection and Space Maintenance of PROVISC® OVD

- High molecular weight to maximize space maintenance in the anterior chamber and capsular bag.
- Excellent clarity and easy removal.



Accept no substitute system for the genuine endothelium protection offered by chondroitin sulfate

Complete removal of OVD's is recommended. See precautions below.

DUOVISC® Viscoelastic System is designed to give two viscoelastic materials with different physico-chemical properties that can be used differently and/or sequentially to perform specific tasks during a cataract procedure. **DUOVISC®** Viscoelastic System consists of **VISCOAT®** Ophthalmic Viscosurgical Device and **PROVISC®** Ophthalmic Viscosurgical Device.

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

VISCOAT® OVD (Sodium Chondroitin Sulfate – Sodium Hyaluronate) Ophthalmic Viscosurgical Device

INDICATIONS: VISCOAT® OVD is indicated for use as an ophthalmic surgical aid in anterior segment procedures including cataract extraction and intraocular lens (IOL) implantation. Viscoat maintains a deep anterior chamber during anterior segment surgeries, enhances visualization during the surgical procedure, and protects the corneal endothelium and other ocular tissues. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery.

WARNINGS: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury.

PRECAUTIONS: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material.

ADVERSE REACTIONS: VISCOAT® OVD has been extremely well tolerated in human and animal studies. A transient rise in intraocular pressure in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to

effect such a rise. It is therefore recommended that Viscoat be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber.

ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions.

PROVISC® OVD (Sodium Hyaluronate) Ophthalmic Viscosurgical Device

INDICATIONS: ProVisc® OVD is indicated for use as an ophthalmic surgical aid in the anterior segment during cataract extraction and intraocular lens (IOL) implantation. Ophthalmic viscoelastics serve to maintain a deep anterior chamber during anterior segment surgery allowing reduced trauma to the corneal endothelium and surrounding ocular tissues. They help push back the vitreous face and prevent formation of a flat chamber during surgery.

PRECAUTIONS: Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should be carefully monitored and appropriate therapy instituted if significant increases should occur. It is recommended that **PROVISC® OVD** be removed by irrigation and/or aspiration at the close of surgery. Do not overfill anterior chamber. Although sodium hyaluronate is a highly purified biological polymer, the physician should be aware of the potential allergic risks inherent in the use of any biological material; care should be used in patients with hypersensitivity to any components in this material. Cannula assembly instructions should be followed to prevent patient injury.

ADVERSE REACTIONS: Postoperative inflammatory reactions such as hypopyon and iritis have been reported with the use of ophthalmic viscoelastics, as well as incidents of corneal edema, corneal decompensation, and a transient rise in intraocular pressure.

ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions.

References: 1. DuoVisc® OVD Product Insert. 2. Poyer JF, Chan KY, Arshinoff SA. New method to measure the retention of viscoelastic agents on a rabbit corneal endothelial cell line after irrigation and aspiration. *J Cataract Refract Surg.* 1998 Jan;24(1):84-90.



Viscoelastic System
DuoVisc®
One System. No Compromises.